Vascular Organoids Help Rebuild the Heart’s Smallest Blood Vessels After Ischemic Injury

by Amanda Chase, PhD
July 16, 2026

Restoring blood flow after a heart attack can save heart muscle and improve survival, but reopening a blocked coronary artery does not always restore circulation throughout the heart. Even after procedures such as percutaneous coronary intervention or coronary artery bypass grafting successfully treat the major coronary vessels, damage to the much smaller vessels embedded within the heart muscle can persist. This microvascular dysfunction limits the delivery of oxygen to recovering tissue, contributes to progressive enlargement and weakening of the heart, and can ultimately lead to ischemic heart failure. Yet there is currently no established treatment specifically designed to restore this damaged microcirculation.

In a new study published in Stem Cell Reports, investigators from the Stanford Cardiovascular Institute developed a scaffold-free vascular organoid, a thin, living sheet of vessel-forming cells, and tested whether it could promote microvascular repair after ischemic injury. The study was led by co-first authors John Farag, Shin Yajima, and Yujiro Kawai, with senior author Yasuhiro Shudo. The organoid combined two complementary human cell populations: endothelial progenitor cells, which can form the inner lining of blood vessels, and smooth muscle-like cells derived from mesenchymal stem cells, which provide structural support and help vessels mature. By arranging the cells in a flexible two-layer construct, the researchers sought to recreate the cellular organization needed to form stable blood vessels without relying on a synthetic scaffold.

Two weeks after the initial injury, the vascular organoids were applied directly over the damaged region and its surrounding border zone. Cardiac MRI was then used to follow changes in heart function and structure over the next four weeks.

The treated and untreated hearts followed distinctly different trajectories. Left ventricular ejection fraction, a measure of how effectively the heart pumps blood, improved by more than four percentage points in animals receiving the vascular organoids but declined by nearly four percentage points in untreated controls. The treated hearts also showed substantially less ventricular enlargement and more favorable changes in cardiac mass. Together, these findings were consistent with preservation of heart function and slower adverse remodeling following the ischemic injury.

Analysis of the heart tissue provided insight into how the therapy produced this benefit. Human cells from the organoids remained detectable four weeks after transplantation, migrated from the surface of the heart into the injured border zone, and became incorporated into blood vessels within the host tissue. Treated hearts contained markedly more endothelial cells and more vessels displaying features of vascular maturation. Importantly, only a small proportion of the endothelial cells in these vessels were derived directly from the transplanted human cells. This suggests that the organoids did more than supply building blocks for new vessels: they also released signals that recruited and activated the heart’s own vascular repair mechanisms.

Gene-expression analysis supported this interpretation. In the ischemic border zone, vascular organoid treatment altered the activity of hundreds of genes and increased programs associated with blood-vessel growth, cellular responses to low oxygen, cell migration, and remodeling of the extracellular environment. These molecular changes were concentrated in the region surrounding the injury rather than in unaffected areas of the heart, further indicating that the organoids generated a localized regenerative response.

The delivery strategy is an important part of the study’s innovation. Cells administered through the bloodstream may disperse before reaching the heart, while cells injected directly into the myocardium can be rapidly lost and may introduce additional tissue injury. Biomaterial-based cardiac patches can improve localization but may restrict the movement of the beating heart or provoke toxicity and immune reactions. In contrast, the scaffold-free organoid remained localized while conforming to the heart’s surface. Its component cells can also be obtained from donor blood and bone marrow, expanded, and potentially banked in advance, offering a possible path toward a readily available therapeutic product.

The study represents an early proof of concept, with a small number of animals, a one-month follow-up period, and immunosuppression required for the transplantation of human cells. Larger and longer studies will be necessary to determine the durability, safety, and optimal delivery of the therapy. Nevertheless, the findings demonstrate that a living vascular construct placed on the heart can stimulate microvascular regeneration and preserve cardiac function in a large-animal model. Rather than replacing conventional coronary interventions, vascular organoid therapy could eventually complement them by addressing the small-vessel damage that remains after major blood flow has been restored. More broadly, the work suggests that engineered tissues may repair the heart not only by supplying new cells, but also by mobilizing the heart’s own regenerative capacity.

Other Stanford authors include Koji Kawago, Eric Pfrender, Umayr Syed, Jennifer Lyons, Tsuyoshi Ueyama, Hiroyuki Takashima, Yuka Matsuura, Gentaro Ikeda, Yu Liu, Yuanjia Zhu, Stefan Elde, Phillip Yang, and Joseph Woo. This project also benefited from early support through a 2020 Stanford Cardiovascular Institute and Steven M. Gootter Foundation Seed Grant Award.